MIPSCo-mRNA-RBD-1
/ Monash University, University of Melbourne, The Peter Doherty Institute for Infection and Immunity
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 15, 2023
Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults
(clinicaltrials.gov)
- P1 | N=76 | Completed | Sponsor: University of Melbourne | Recruiting ➔ Completed
Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8 • IFNG • IL4
1 to 1
Of
1
Go to page
1